Literature DB >> 26855151

A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.

G O'Kane1, D Bracken-Clarke2, N Gardiner2, G Lee2, M Ni Chonghaile2, D Power3, P A Daly1, J McCaffrey4, C L Bacon2, E Conneally2, C Flynn2, E Vandenberghe2, M J Kennedy1, P V Browne2, D M O'Donnell1, P J Hayden2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26855151     DOI： 10.1038/bmt.2015.354

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.

Authors:  G Varuni Kondagunta; Jennifer Bacik; Joel Sheinfeld; Dean Bajorin; Manjit Bains; Lillian Reich; John Deluca; Amy Budnick; Nicole Ishill; Madhu Mazumdar; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

2.  Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.

Authors:  G Varuni Kondagunta; Jennifer Bacik; Alessia Donadio; Dean Bajorin; Stephanie Marion; Joel Sheinfeld; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

3.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

Authors:  R J Motzer; M Mazumdar; J Sheinfeld; D F Bajorin; H A Macapinlac; M Bains; L Reich; C Flombaum; T Mariani; W P Tong; G J Bosl
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.

Authors:  Darren R Feldman; Joel Sheinfeld; Dean F Bajorin; Patricia Fischer; Stefan Turkula; Nicole Ishill; Sujata Patil; Manjit Bains; Lilian M Reich; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Authors:  Anja Lorch; Jörg Beyer; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence H Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim A Margolin; Jean-Pierre Lotz; Jose Ramon Germa Lluch; Thomas Powles; Christian K Kollmannsberger
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

8.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.

Authors:  Lawrence H Einhorn; Stephen D Williams; Amy Chamness; Mary J Brames; Susan M Perkins; Rafat Abonour
Journal:  N Engl J Med       Date:  2007-07-26       Impact factor: 91.245

9.  High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.

Authors:  J Lewin; M Dickinson; M Voskoboynik; M Collins; D Ritchie; G Toner
Journal:  Intern Med J       Date:  2014-08       Impact factor: 2.048

10.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.